Spac backtrack confirms that the gene therapy bubble has burst
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Glaxosmithkine and Merck & Co succumb to the urge to demerge, joining other big drug makers in pruning their businesses.
The combination of Upjohn and Mylan means that, for a change, Pfizer is getting smaller. But will the company’s new chief executive really be able to resist the urge to…